Skip to main content
. 2022 Mar 4;10(3):609. doi: 10.3390/biomedicines10030609
ICPi immune checkpoint inhibitors
CTLA-4 cytotoxic T-lymphocyte-associated protein 4
PD-1 programmed cell death protein 1
PD-L1 programmed death-ligand 1
IRAEs immune related adverse events
CD celiac disease
AD autoimmune disease
TCR T cell receptor
tTG tissue transglutaminase
APCs antigen presenting cells
MHC histocompatibility complex